Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

50.50USD
29 Aug 2014
Price Change (% chg)

$-0.04 (-0.08%)
Prev Close
$50.54
Open
--
Day's High
--
Day's Low
--
Volume
539,130
Avg. Vol
7,402,654
52-wk High
$57.49
52-wk Low
$41.32

BMY

Chart for BMY

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.40
Market Cap (Mil.): $83,972.88
Shares Outstanding (Mil.): 1,657.91
Dividend: 0.36
Yield (%): 2.84

Financials

  BMY Industry Sector
P/E (TTM): 31.41 32.30 33.23
EPS (TTM): 1.61 -- --
ROI: 10.07 17.96 17.21
ROE: 18.10 18.60 18.01
Search Stocks

Germany's Bayer to launch three new Xarelto trials

FRANKFURT - Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines.

29 Aug 2014

Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

LOS ANGELES - U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

25 Aug 2014

FDA approves use of Eliquis to treat leg, lung clots

- Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

21 Aug 2014

UPDATE 1-FDA approves use of Eliquis to treat leg, lung clots

Aug 21 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.

21 Aug 2014

FDA OKs use of Eliquis to treat leg, lung clots

Aug 21 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

21 Aug 2014

ConvaTec owners eye 2015 sale as buyout interest builds: sources

NEW YORK - ConvaTec's private equity owners plan to explore a sale of the medical device maker next year, even as interest from several healthcare companies in a potential $10 billion acquisition intensifies, according to people familiar with the matter.

18 Aug 2014

ConvaTec owners eye 2015 sale as buyout interest builds-sources

NEW YORK, Aug 18 - ConvaTec's private equity owners plan to explore a sale of the medical device maker next year, even as interest from several healthcare companies in a potential $10 billion acquisition intensifies, according to people familiar with the matter.

18 Aug 2014

Bristol-Myers profit tops forecasts, helped by newer drugs

- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.

24 Jul 2014

UPDATE 2-Bristol-Myers profit tops forecasts, helped by newer drugs

(Adds analyst comment, shares, details on immuno-oncology drugs)

24 Jul 2014

Bristol-Myers profit tops forecasts, helped by newer drugs

July 24 - Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma.

24 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.73 +0.78
Pfizer Inc. (PFE.N) $29.39 +0.01
Merck & Co., Inc. (MRK.N) $60.11 +0.11
Sanofi SA (SASY.PA) €83.54 +0.04
AstraZeneca plc (AZN.L) 4,577.50p +10.50
GlaxoSmithKline plc (GSK.L) 1,460.00p -14.50
Eli Lilly and Co (LLY.N) $63.56 +0.45

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks